Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Optical genome mapping to detect abnormalities in AML

Sanam Loghavi • 14 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses optical genome mapping as a method of detecting cryptic genetic abnormalities in acute myeloid leukemia (AML). Notably, this study detected KMT2A partial tandem duplications and NUP98 rearrangements, which may have a clinical impact. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Sanam Loghavi

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
36:15
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
Amer Zeidan et al. • 19 Mar 2026
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
1:35
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
Sanam Loghavi • 6 Dec 2025
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
2:21
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
Sanam Loghavi • 6 Dec 2025

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals